
Webinar
GOC-ESGO 2nd Joint Webinar: Mirvetuximab Soravtansine (MIRV) and the Growing Real-World Evidence Emerging from European Practice
Joint ESGO–GOC webinar on mirvetuximab soravtansine in ovarian cancer and emerging real-world evidence from European practice.
Date & time
Start November 24, 2026
End November 24, 2026
Location
Country Online
Event format Virtual
People & organizations
Organizer(s) European Society of Gynaecological Oncology (ESGO); GOC